## **Appendix 3X**

#### **Initial Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity:	Neuren Pharmaceuticals Limited
ABN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr David John Clarke
Date of appointment	22 October 2004

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part

#### Number & class of securities

Holder of 4,241,888 unlisted options to acquire Ordinary Shares at NZ\$0.39 ( A\$0.36 ) each at any time until March 2009, subject to escrow restrictions.

<sup>+</sup> See chapter 19 for defined terms.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of	Number & class of Securities
interest	
Note: Provide details of the circumstances giving rise to the relevant interest.	
	NIL

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	NIL
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

<sup>+</sup> See chapter 19 for defined terms.

## **Appendix 3X**

### **Initial Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity:	Neuren Pharmaceuticals Limited
ABN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr John Douglas Wilson
Date of appointment	17 June 2004

## Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities		
NIL		

<sup>+</sup> See chapter 19 for defined terms.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of	Number & class of Securities
interest	
Note: Provide details of the circumstances giving rise to the relevant interest.	
	NIL

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	NIL
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3X**

### **Initial Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity:	Neuren Pharmaceuticals Limited
ABN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Robin Lance Congreve
Date of appointment	17 December 2001

## Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities		
N/A		

<sup>+</sup> See chapter 19 for defined terms.

# ${\bf Part~2-Director's~relevant~interests~in~securities~of~which~the~director~is~not~the~registered~holder}$

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of	Number & class of Securities
interest Note: Provide details of the circumstances giving rise to the relevant interest.  1. T.A.C. Murray and Quartet Equities Limited as trustees of The Congreve Family Trust and the relevant interest is as a beneficiary of The Congreve Family Trust	3,704,244 Ordinary Shares
2. EndocrinZ Founders Limited and the relevant interest is as a director and shareholder	1,605,336 Ordinary Shares
3. Oceania & Eastern Biotech Limited and the relevant interest is as a director and indirect shareholding held by associated interests	2,686,926 Ordinary Shares and 1,528,892 unlisted options to acquire Ordinary Shares at NZ\$0.39 (A\$0.36) each until March 2009 subject to escrow restrictions
4. Hazardous Investments Limited and the relevant interest is as a director and indirect shareholding held by associated interests	3,293,711 Ordinary Shares
5. NeuronZ Limited and the relevant interest is as a director	12,345,898 Ordinary Shares

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
	NIL
Nature of interest	
Name of registered holder	
(if issued securities)	
No. and class of securities to	
which interest relates	

<sup>+</sup> See chapter 19 for defined terms.

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3X

### **Initial Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity:	Neuren Pharmaceuticals Limited
ABN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr. Thomas Robert Amos
Date of appointment	9 November 2004

## Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<sup>+</sup> See chapter 19 for defined terms.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of	Number & class of Securities
interest  Note: Provide details of the circumstances giving rise to the relevant interest.	
Perpetual Trustee Company     Limited ATF – Macquarie     Technology Fund 1 A and     Mr Amos has a relevant     interest as a representative     of the trust	4,812,059 Ordinary Shares
2. Perpetual Trustee Company (Canberra) Limited ATF – Macquarie Technology Fund 1 B and Mr Amos has a relevant interest as a representative of the trust	4,812,059 Ordinary Shares

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	NIL
Nature of interest	
Name of registered holder	
(if issued securities)	
No. and class of securities to which interest relates	
which interest relates	

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3X**

### **Initial Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity:	Neuren Pharmaceuticals Limited
ABN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr. Trevor Donald Scott
Date of appointment	5 March 2002

## Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<sup>+</sup> See chapter 19 for defined terms.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of	Number & class of Securities
interest  Note: Provide details of the circumstances giving rise to the relevant interest.	
1. The New Zealand Seed Fund Management Limited and the relevant interest as a director	11,441,670 Ordinary Shares
2. Centralo Limited and the relevant interest as a director	991,125 Ordinary Shares

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

NIL

<sup>+</sup> See chapter 19 for defined terms.